(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from INPI

MÉTODO DE TRATAMENTO DA PSORÍASE E OUTRAS CONDIÇÕES AUTO-IMUNES COM UM INIBIDOR PRMT5

ArquivadaInvention PatentPCT · IB2021050013

Application data

Number

112022010495

Type

Invention Patent

Filing

01/04/2021

Publication

09/06/2022

PCT

IB2021050013

Progress at the INPI

  1. Filing01/04/21
  2. Publication09/06/22
  3. Abandoned
  4. Allowance
  5. Grant
  6. In force

The application was abandoned: examination was not requested within the 36 months following the 01/04/2021 filing, the deadline set by art. 33 of the Brazilian IP Act. The technology is in the public domain in Brazil.

Talk to a specialist

Latest action published by the INPI: 04/16/2024. We update with every new RPI gazette, published weekly.

Applicants and inventors

Applicants

PFIZER INC.

US

See this company's full portfolio

Inventors

A. T. (pessoa física)

US

M. L. (pessoa física)

US

Technical data

Priority claims

US

62/957,925 · 01/07/2020

US

63/116,120 · 11/19/2020

Abstract

MÉTODO DE TRATAMENTO DA PSORÍASE E OUTRAS CONDIÇÕES AUTO-IMUNES COM UM INIBIDOR PRMT5.Uso de inibidor PRMT5 tal como e incluindo (1S,2S,3S,5R)-3-((6-(difluorometil)-5-fluoro-1,2,3,4-tetra-hidroisoquinolin-8-il)óxi)-5-(4-metil-7H-pirrolo[2,3-d]pirimidin-7-il)ciclopentano-1,2-diol: , ou um sal farmaceuticamente aceitável deste, para tratar a psoríase, lúpus eritematoso sistêmico (LES), artrite reumatoide (AR), artrite psoriática e outras condições ou distúrbios auto-imunes.

Prosecution history

Publications in the Brazilian Industrial Property Gazette (RPI).

Arquivamento definitivo - Art. 33 da LPI

#11.1.1

04/16/2024

RPI 2780

Arquivamento - Art. 33 da LPI

#11.1

01/30/2024

RPI 2769

Alteração de sede deferida

#25.7

08/08/2023

RPI 2744

Notificação de entrada na fase nacional - PCT

#1.3

09/06/2022

RPI 2696

Alteração de dados cadastrais

#1.1

06/07/2022

RPI 2683

Patent monitoring

Track this patent in real time.

Receive alerts on INPI events, decisions, and expiry dates for your portfolio.